Vaxcyte (NasdaqGS:PCVX) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAndrew Guggenhime - President and CFOAsad Haider - Managing DirectorDina Ramadane - Biotech Equity Research AssociateEvan Wang - VP, Equity ResearchGrant Pickering - CEOJim Wassil - EVP and COOJonathan Miller - Equity Research AssociateMike Miletich - Chief Commercial OfficerConference Call ParticipantsCarter Gould - Managing Director and Senior AnalystJoseph Stringer - Senior AnalystRoger Song - Senior Equity Re ...

Vaxcyte (NasdaqGS:PCVX) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAndrew Guggenhime - President and CFOAsad Haider - Managing DirectorDina Ramadane - Biotech Equity Research AssociateEvan Wang - VP of Equity ResearchGrant Pickering - CEOJim Wassil - EVP and COOJonathan Miller - Managing Director of Biotech and Pharma Equity ResearchMike Miletich - Chief Commercial OfficerConference Call ParticipantsCarter Gould - Managing Director and Senior AnalystJoseph Stringer - Senior Anal ...

Vaxcyte (NasdaqGS:PCVX) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker13Good afternoon. My name is Chloe. I will be your conference operator for the Vaxcyte fourth quarter and full year 2025 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer period. If you would like to ask a question during this time, simply press star followed by 1 on your telephone keypad. If you would like to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________ FORM 10-K ______________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ______ ...

Exhibit 99.1 Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Stu ...

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Exp ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, representing a substantial shift in the global economy driven by AI innovations [2] - Major firms like PwC and McKinsey acknowledge that AI could unlock multi-trillion-dollar opportunities, reinforcing the optimistic outlook on AI's economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is believed to be redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, suggesting potential investment opportunities [4] - Prominent figures in technology and finance, including Bill Gates and Warren Buffett, recognize AI as a significant technological advancement with the potential for broad societal benefits [8]

Group 1 - Vaxcyte Inc. (NASDAQ:PCVX) is recognized as one of the 13 hot stocks with significant upside potential, having recently closed a public offering of 12.65 million shares at $50 per share, raising $632.5 million in gross proceeds [1][6] - Cantor Fitzgerald has reiterated an Overweight rating on Vaxcyte, highlighting that the company's clinical pipeline is on track, with a topline readout from the Phase 3 OPUS-1 trial expected in Q4 2026 and a Biologics License Application filing planned for 2027 [2] - The company specializes in developing vaccines for infectious diseases, focusing on conjugate and protein-based vaccines utilizing a cell-free protein synthesis technology platform [3]

Vaxcyte Incorporated (NASDAQ:PCVX) is one of the 17 biotechnology stocks with more than 50% upside. On January 23, Cantor Fitzgerald maintained its Overweight rating on Vaxcyte Incorporated (NASDAQ:PCVX), highlighting continued progress across the company’s clinical pipeline. The firm reflected on the topline readout from the Phase 3 OPUS-1 trial, expected in the fourth quarter of 2026, with a planned BLA filing the following year. OPUS-2 has already begun participant dosages, and OPUS-3 is set to start i ...

Summary of Vaxcyte Conference Call Company Overview - **Company**: Vaxcyte - **Focus**: Development of pneumococcal conjugate vaccines, particularly the VAX-31 program Key Industry Insights - **Vaccine Market**: The pneumococcal conjugate vaccine segment is currently valued at **$8 billion** and is expected to grow significantly as adult vaccination rates increase, similar to those of children [3][8] - **Market Dynamics**: The market has seen a shift with increasing recommendations for adult vaccinations outside the U.S., leading to growth opportunities in global markets [8][9] Core Product Insights - **VAX-31 Program**: - A **31-valent** vaccine that aims to provide broader coverage than existing vaccines, which are limited to **20 or 21 serotypes** [6][12] - Phase 2 data showed improved immune responses while expanding coverage, leading to confidence in Phase 3 trials [12][20] - The pivotal study, OPUS 1, will involve **4,000 subjects** aged 50 and older, comparing VAX-31 to current standard vaccines [13][34] Competitive Landscape - **Current Competitors**: - **Prevnar 20**: Market leader with a focus on older serotypes - **CAPVAXIVE**: A newer entrant with broader coverage of circulating serotypes [22][24] - **Market Positioning**: Vaxcyte aims to position VAX-31 as a superior option by covering both older and newer serotypes, potentially capturing significant market share as the market evolves [23][24] Regulatory and Commercial Strategy - **Regulatory Environment**: Vaxcyte is working closely with the FDA to ensure that the Phase 3 program meets higher standards for non-inferiority, reflecting a shift in regulatory expectations [14][19] - **Commercial Strategy**: The company plans to be selective in its commercialization approach, potentially partnering in certain markets while pursuing direct sales in others [10][11] Financial Position - **Funding**: Vaxcyte recently raised over **$3 billion** in cash, providing a strong financial position to support upcoming milestones, including the potential approval and launch of VAX-31 in **2028** [61] Additional Insights - **Catch-Up Vaccination**: There is a significant opportunity for catch-up vaccinations for adults who have previously received older vaccines, which could expand the market further [43][44] - **Pediatric Program**: Vaxcyte is also developing a pediatric version of the vaccine, with expectations for Phase 2 data in the near future [52][56] - **Otitis Media Opportunity**: VAX-31 has the potential to significantly reduce cases of acute otitis media in children, which is often caused by pneumococcal infections [58][59] Conclusion Vaxcyte is positioned to capitalize on the growing pneumococcal vaccine market with its innovative VAX-31 program, backed by strong financial resources and a strategic approach to commercialization and regulatory compliance. The company aims to address both adult and pediatric markets, with a focus on broadening vaccine coverage and improving health outcomes.